DocWire News Editors

DocwireNews

The use of colchicine can reduce inflammation during percutaneous coronary intervention (PCI), according to the findings of a new study presented at the American Heart Association 2019 Scientific Sessions in Philadelphia.The researchers noted that vascular injury and inflammation during PCI results in rapid neutrophil recruitment to the trauma site and is correlated with endothelial cell and microvascular dysfunction. Injury and inflammation are independent predictors of subsequent major adverse cardiovascular events (MACE), even in the contemporary era with assess to second-generation drug-eluting stents (DES).To conduct this double-blind trial, researchers assessed 400 study subjects who underwent PCI and were randomized to receive colchicine or a placebo. The sample size of 400 provided the researchers with an 80% power to detect a 40% reduction in the primary endpoint, which was defined as peri-procedural myocardial injury within 24 hours post-PCI. The study&rsquo;s secondary endpoint was specified as the composite of non-fatal myocardial infarction, target vessel revascularization, and all-cause mortality at 30 days.According to the results of the study, compared with placebo, short-term pre-procedural colchicine did not reduce PCI-related myocardial injury or MACE at 30 days. However, colchicine did attenuate PCI-related increase in both IL-6 and hsCRP concentration at 24 hours post-PCI, indicating that the therapy effectively mitigated the increase in inflammation after PCI when compared with placebo.&ldquo;This is the first study to demonstrate that an oral load of colchicine prevents a rise of inflammatory biomarkers in acute injury,&rdquo; lead researcher Binita Shah, MD, of New York University (NYU) School of Medicine, noted in a presentation.On study limitations, Dr. Shah said: &ldquo;Genetic data were not collected in the current trial to determine predisposition to colchicine resistance.&rdquo;

Jordana Jampel

FDA Approves Novel Blood Test for Alzheimer’s Detection

Dementia

Andrew Moreno

Is Plasma Mannose-Binding Lectin a Clue to Higher VTE Risk?

Katie Kosko

EMBER-3: Imlunestrant Plus Abemaciclib Improves PFS in ER+ Breast Cancer

HR Breast Cancer

Latest News

Colchicine in PCI Linked with Reduced Inflammation

AHA 2019

The use of colchicine can reduce inflammation during percutaneous coronary intervention (PCI), according to the findings of a new study presented at the American Heart ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe